Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N. Graf RP, et al. Among authors: oxnard gr. JAMA Netw Open. 2022 Mar 1;5(3):e225394. doi: 10.1001/jamanetworkopen.2022.5394. JAMA Netw Open. 2022. PMID: 35357449 Free PMC article.
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
Graf RP, Fisher V, Creeden J, Schrock AB, Ross JS, Nimeiri H, Oxnard GR, Klempner SJ. Graf RP, et al. Among authors: oxnard gr. Cancer Res Commun. 2022 Sep 21;2(9):1037-1048. doi: 10.1158/2767-9764.CRC-22-0161. eCollection 2022 Sep. Cancer Res Commun. 2022. PMID: 36922935 Free PMC article.
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, Ross JS, Huang RSP, Schrock AB, Oxnard GR, Chakrabarti S, Mahipal A. Quintanilha JCF, et al. Among authors: oxnard gr. JCO Precis Oncol. 2023 Jul;7:e2300092. doi: 10.1200/PO.23.00092. JCO Precis Oncol. 2023. PMID: 37410975 Free PMC article.
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Graf RP, et al. Among authors: oxnard gr. Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26. Eur Urol. 2022. PMID: 34716049 Free article.
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Zurita AJ, et al. Among authors: oxnard gr. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. JCO Precis Oncol. 2022. PMID: 35820087 Free PMC article.
200 results